JP2018531620A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018531620A5 JP2018531620A5 JP2018529689A JP2018529689A JP2018531620A5 JP 2018531620 A5 JP2018531620 A5 JP 2018531620A5 JP 2018529689 A JP2018529689 A JP 2018529689A JP 2018529689 A JP2018529689 A JP 2018529689A JP 2018531620 A5 JP2018531620 A5 JP 2018531620A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- mutation
- nucleic acid
- determination
- level
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2015903456A AU2015903456A0 (en) | 2015-08-26 | Methods of detecting cancer recurrence | |
| AU2015903456 | 2015-08-26 | ||
| PCT/AU2016/050799 WO2017031551A1 (en) | 2015-08-26 | 2016-08-26 | Methods of detecting cancer recurrence |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018531620A JP2018531620A (ja) | 2018-11-01 |
| JP2018531620A5 true JP2018531620A5 (https=) | 2019-10-03 |
| JP6850294B2 JP6850294B2 (ja) | 2021-03-31 |
Family
ID=58099416
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018529689A Active JP6850294B2 (ja) | 2015-08-26 | 2016-08-26 | 癌の再発を検出する方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11225690B2 (https=) |
| EP (1) | EP3341496B1 (https=) |
| JP (1) | JP6850294B2 (https=) |
| CN (2) | CN116574809A (https=) |
| AU (1) | AU2016310415B2 (https=) |
| ES (1) | ES2873841T3 (https=) |
| WO (1) | WO2017031551A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016310415B2 (en) | 2015-08-26 | 2022-04-21 | Gmdx Co Pty Ltd | Methods of detecting cancer recurrence |
| EP3500966B1 (en) | 2016-08-25 | 2021-04-21 | Nantomics, LLC | Immunotherapy markers and uses therefor |
| EP3710600B1 (en) * | 2017-11-17 | 2025-03-12 | GMDx Co Pty Ltd | Systems and methods for predicting the efficacy of cancer therapy |
| CN108796077B (zh) * | 2018-05-30 | 2021-11-09 | 朱运峰 | 在cfDNA中检测胞嘧啶脱氨酶及相关分子基因修饰差异的引物对组及试剂盒 |
| WO2021243401A1 (en) * | 2020-06-01 | 2021-12-09 | Gmdx Co Pty Ltd | Methods of predicting cancer progression |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| BR9707495A (pt) | 1996-02-13 | 1999-07-27 | Zeneca Ltd | Derivado de quinazolina processo para a preparação do mesmo composição farmacêutica e processo para a produç o de um efeito antiangiogênico e/ou de redução de permeabilidade vascular em um animal de sangue quente |
| US6291455B1 (en) | 1996-03-05 | 2001-09-18 | Zeneca Limited | 4-anilinoquinazoline derivatives |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| NZ522074A (en) | 2000-05-31 | 2004-06-25 | Astrazeneca Ab | Indole derivatives with vascular damaging activity |
| IL153484A0 (en) | 2000-07-07 | 2003-07-06 | Angiogene Pharm Ltd | Colchinol derivatives as angiogenesis inhibitors |
| CN1255392C (zh) | 2000-07-07 | 2006-05-10 | 安吉奥金尼药品有限公司 | 作为血管生成抑制剂的秋水仙醇衍生物 |
| ES2674928T3 (es) * | 2012-11-05 | 2018-07-05 | Gmdx Co Pty Ltd | Métodos para determinar la causa de la mutagénesis somática |
| AU2016310415B2 (en) | 2015-08-26 | 2022-04-21 | Gmdx Co Pty Ltd | Methods of detecting cancer recurrence |
-
2016
- 2016-08-26 AU AU2016310415A patent/AU2016310415B2/en active Active
- 2016-08-26 ES ES16838136T patent/ES2873841T3/es active Active
- 2016-08-26 CN CN202310693406.1A patent/CN116574809A/zh not_active Withdrawn
- 2016-08-26 WO PCT/AU2016/050799 patent/WO2017031551A1/en not_active Ceased
- 2016-08-26 US US15/754,983 patent/US11225690B2/en active Active
- 2016-08-26 CN CN201680062714.2A patent/CN108603231B/zh active Active
- 2016-08-26 EP EP16838136.6A patent/EP3341496B1/en active Active
- 2016-08-26 JP JP2018529689A patent/JP6850294B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Liang et al. | Gastric cancer and gene copy number variation: emerging cancer drivers for targeted therapy | |
| JP2018531620A5 (https=) | ||
| Edlundh-Rose et al. | NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing | |
| JP2020143146A5 (https=) | ||
| Thieu et al. | The role of microRNA in castration-resistant prostate cancer | |
| JP2010538609A5 (https=) | ||
| JPWO2019004080A1 (ja) | 融合遺伝子及び／又はエクソンスキッピングにより生ずる転写産物を検出するためのプローブ及び方法 | |
| JP6850294B2 (ja) | 癌の再発を検出する方法 | |
| WO2017075784A1 (zh) | 肺腺癌生物标记物及其应用 | |
| JP6489658B2 (ja) | 肝細胞癌において分子標的治療の感受性を増加させるための分析方法 | |
| Salmaninejad et al. | Molecular characterization of KRAS, BRAF, and EGFR genes in cases with prostatic adenocarcinoma; reporting bioinformatics description and recurrent mutations | |
| Roy et al. | Genetics and epigenetics of breast cancer | |
| Ranjbari et al. | BRAF mutations in Iranian patients with papillary thyroid carcinoma | |
| Gallegos-Arreola et al. | Pathophysiology of acute lymphoblastic leukemia | |
| Jeon et al. | Low prevalence of somatic TERT promoter mutations in classic papillary thyroid carcinoma | |
| Hudler | Outlook on epigenetic therapeutic approaches for treatment of gastric cancer | |
| Wang et al. | EGFR/KRAS mutations and gefitinib therapy in Chinese NSCLC patients | |
| Malicherova et al. | Detection of driver mutations in FFPE samples from patients with verified malignant melanoma. | |
| US20220243274A1 (en) | Method for predicting response to anticancer immunotherapy using dna methylation aberration | |
| Strzelczyk et al. | Expression profiles of MGMT, p16, and APC genes in tumor and matching surgical margin from patients with oral squamous cell carcinoma | |
| CN113564250B (zh) | 头颈部癌症的生物标志物及其使用方法 | |
| US20230257823A1 (en) | Biomarkers for identifying patients at high risk of progressing from barrett's esophagus to esophageal adenocarcinoma | |
| Kanwal et al. | Hypo/unmethylated promoter status of Cdk2 gene correlates with its over-expression in ovarian cancer in north Indian population | |
| Jamil et al. | Association of EGFR gene polymorphism in head and neck cancer patients with tobacco and alcohol consuming habits | |
| Hama et al. | KRAS and MT-CO1 genes in colorectal cancer: a molecular investigation |